Screener
Allogene Therapeutics ALLO Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Proceeds from issuance of common stock upon exercise of stock options | 4 | — |
| Proceeds from issuance of common stock under the employee stock purchase plan | 450 | 638 |
| Net cash provided by financing activities | 21,122 | 13,990 |
| Net change in cash and cash equivalents and restricted cash | (21,379) | (32,763) |
| Cash and cash equivalents and restricted cash — beginning of period | 61,980 | 85,510 |
| Cash and cash equivalents and restricted cash — end of period | $40,601 | $52,747 |
| Non-cash operating activities: | ||
| Property and equipment purchases in accounts payable and accrued liabilities | $146 | — |
Item 1. Financial Statements - Unaudited
FAQ
- What is Allogene Therapeutics's net change in cash?
- Allogene Therapeutics (ALLO) reported net change in cash of -$21.38M in Q1 2026.
- How has Allogene Therapeutics's net change in cash changed year-over-year?
- Allogene Therapeutics's net change in cash increased by 34.7% year-over-year, from -$32.76M to -$21.38M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Allogene Therapeutics's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude